Early Metabolic Alterations in Cerebrospinal Fluid Fatty Acid Profiles Linked to Cognitive Decline and All-Cause Dementia
Jacob Apibilla AyembillaiD, Yannick N. WadopiD, Rebecca BernaliD, Biniyam Alemayehu AyeleiD, Muralidharan SargurupremrajiD, Xueqiu JianiD, Alfred Kongnyu NJAMNSHIiD, Sudha S. SeshadriiD, Alice B. S. Nono Djotsa, Jayandra Jung HimaliiD, Bernard FongangiD, Alfred Nji FontehiD
Abstract
BackgroundWhile All-cause dementia (ACD) may often be characterized by the abnormal deposition of extracellular {beta}-amyloid (A{beta}) in the brain cortex and hyperphosphorylated tau (p-tau) as neurofibrillary tangles intracellularly, there is a need to identify early metabolic changes that may accompany these pathological changes. ObjectiveThis study evaluated the predictive value of fatty acids in cerebrospinal fluid (CSF) fractions in differentiating cognitively unimpaired (CU), mild cognitive impairment (MCI), and ACD participants. MethodsCSF fatty acid profiles were analyzed from CU (n=68), MCI (n=38), and ACD (n=37) individuals aged 77.3 {+/-} 7.7 years, sourced from the Huntington Medical Research Institutes (HMRI). Multivariable binary logistic regression identified the most effective CSF fatty acid biomarkers for distinguishing CU, MCI, and ACD groups. The top-performing CSF fatty acid biomarkers were combined with A{beta}42, tau, and the A{beta}42/tau ratio to evaluate their collective diagnostic performance. The model was adjusted for covariates, including age, sex, smoking status, hypertension, diabetes, and APOE genotype. Receiver operating characteristic (ROC) curves were generated for the top 10 CSF fatty acids ranked by area under the curve (AUC), sensitivity, and specificity, and their significance was assessed using the DeLong test. ResultsThe top 10 fatty acids in CSF fractions demonstrated superior discrimination between CU individuals and those with MCI compared to traditional markers such as A{beta}42, tau, and the A{beta}42/tau ratio. Furthermore, incorporating a panel of these fatty acid biomarkers alongside A{beta}42/tau significantly improved diagnostic accuracy. Age, sex, smoking, hypertension, APOE genotype, and diabetes did not significantly influence the models performance. ConclusionThis study suggests that changes in fatty acid metabolism occur in early ACD pathology. Thus, strategies that regulate fatty acid metabolism may prevent cognitive decline in an older population. HighlightsO_LIThis study revealed that CSF fractions fatty acids have a better discriminatory power for CU from MCI than CSF A{beta}42, tau, and A{beta}42/tau ratio. C_LIO_LIA panel of CSF fraction fatty acids combined with A{beta}42/tau remarkably improved its diagnostic performance for differential diagnosis of CU, MCI, and ACD. C_LIO_LIClinical evaluation of these fatty acids will strengthen the detection of early cognitive impairment. A prospective large cohort multicenter study of the diagnostic utility of CSF fractions fatty acids will provide robust evidence before extensive clinical usage of these fatty acids. C_LI
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Age-accelerated cognitive decline in asymptomatic adults with CSF β-amyloid
Lindsay R. Clark, Sara Elizabeth Berman, … Cynthia M. Carlsson·NeurologyPeer-reviewed·Mar 9, 2018
- CSF metabolites associate with CSF tau and improve prediction of Alzheimer's disease status
Ruocheng Dong, Burcu F. Darst, … Corinne D. Engelman·Alzheimer s & Dementia Diagnosis Assessment & Disease MonitoringPeer-reviewed·Jan 1, 2021
- Peripheral Serum Metabolomic Profiles InformAntecedent Central Cognitive Impairment in Older Adults
Jingye Wang, Runmin Wei, … Wei Ping Jia·bioRxiv·Nov 12, 2019
- CSF biomarkers are differentially related to structural and functional changes in dementia of the Alzheimer’s type
Charles Benjamin Malpas, Michael Martin Saling, … Terence John O'Brien·Journal of Alzheimer s DiseasePeer-reviewed·Feb 6, 2018
- Metabolites associated with early cognitive changes implicated in Alzheimer’s disease
Burcu F. Darst, Zhiguang Huo, … Corinne D. Engelman·Journal of Alzheimer s DiseasePeer-reviewed·Jan 8, 2021
- Serum triglycerides in Alzheimer’s disease: Relation to neuroimaging and CSF biomarkers
Megan M. Bernath, Sudeepa Bhattacharyya, … Alzheimer’s Disease Neuroimaging Initiative·bioRxiv·Apr 16, 2019